









Markets
/
Stocks
/
nasdaq-clgn
/

Collplant Biotechnologies Ltd

CLGN



View Detailed Chart

1.520USD

+0.140+10.14%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

19.42MMarket Cap

LossP/E TTM



Collplant Biotechnologies Ltd

1.520

+0.140+10.14%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+10.14%

5 Days

-16.02%

1 Month

-28.97%

6 Months

+3.40%

Year to Date

-57.78%

1 Year

-55.43%

View Detailed Chart

TradingKey Stock Score of Collplant Biotechnologies Ltd

Currency: USD Updated: 2025-12-19

Key Insights

Collplant Biotechnologies Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 134/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Collplant Biotechnologies Ltd's Score

Industry at a Glance

Industry Ranking

134 / 404

Overall Ranking

256 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.500

Target Price

+463.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Collplant Biotechnologies Ltd Highlights

StrengthsRisks

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 72.24% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 515.00K.

Overvalued

The company’s latest PE is -1.48, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 21.90K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.72.